A. Zahlten-Kumeli

发表

Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)

H. Goldschmidt, M. Dimopoulos, S. Iida, 2019, Leukemia.

Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

A. Nooka, Kihyun Kim, T. Facon, 2021, British journal of haematology.

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

M. Dimopoulos, J. H. Lee, R. Hájek, 2019, Blood.

Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible , NDMM patients Running title : KMP vs VMP for newly diagnosed multiple myeloma

M. Dimopoulos, J. H. Lee, P. Moreau, 2019 .

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

H. Goldschmidt, M. Dimopoulos, R. Hájek, 2017, The Lancet. Oncology.

Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma

X. Leleu, K. Weisel, A. Zahlten-Kumeli, 2021, Leukemia & lymphoma.

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.

M. Dimopoulos, P. Moreau, A. Stewart, 2018, The Lancet. Oncology.

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

M. Dimopoulos, D. Siegel, R. Hájek, 2018, Blood.

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

M. Dimopoulos, D. Siegel, A. Oriol, 2020 .

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

M. Dimopoulos, D. Siegel, X. Leleu, 2019 .

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

M. Dimopoulos, X. Leleu, O. Landgren, 2020, The Lancet.

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

M. Dimopoulos, D. Siegel, R. Hájek, 2020, Blood Cancer Journal.

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.

M. Dimopoulos, A. Jakubowiak, A. Oriol, 2021, The Lancet. Oncology.

Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials

M. Dimopoulos, D. Siegel, M. Mateos, 2018, Blood.

Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials

M. Dimopoulos, D. Siegel, R. Orlowski, 2020, Cancer medicine.

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

M. Dimopoulos, D. Siegel, R. Hájek, 2020, Blood Cancer Journal.

Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials

M. Dimopoulos, J. H. Lee, S. Iida, 2019, International Journal of Hematology.

Trial in progress: Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101).

K. Muro, S. Rha, J. Chao, 2022, Journal of Clinical Oncology.

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

M. Dimopoulos, P. Moreau, A. Stewart, 2018, Blood.